Lipid membranes accelerate amyloid formation in the mouse model of AA amyloidosis

References

• Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015;10:321–344.
   PubMed Web of Science ®Google Scholar
• Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002;440:111–122.
   PubMed Web of Science ®Google Scholar
• Hazenberg BPC, van Gameren II, Bijzet J, et al. Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med. 2004;62:121–128.
   PubMed Web of Science ®Google Scholar
• Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23:209–213.
   PubMed Web of Science ®Google Scholar
• Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun. 2000;268:405–408.
   PubMed Web of Science ®Google Scholar
• Patel H, Fellowes R, Coade S, et al. Human serum amyloid A has cytokine-like properties. Scand J Immunol. 1998;48:410–418.
   PubMed Web of Science ®Google Scholar
• Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34–42.
   PubMedGoogle Scholar
• Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20–38.
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417–426.
   PubMed Web of Science ®Google Scholar
• Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010;11:897–904.
   PubMed Web of Science ®Google Scholar
• Niemi K, Teirilä L, Lappalainen J, et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol. 2011;186:6119–6128.
   PubMed Web of Science ®Google Scholar
• Röcken C, Kisilevsky R. Comparison of the binding and endocytosis of high-density lipoprotein from healthy (HDL) and inflamed (HDL(SAA)) donors by murine macrophages of four different mouse strains. Virchows Arch. 1998;432:547–555.
   PubMed Web of Science ®Google Scholar
• Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. J Leukoc Biol. 2015;98:923–929.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Yokota T, Kawano H, et al. Ultrastructural evidence for intracellular formation of amyloid fibrils in macrophages. Virchows Arch A Pathol Anat Histopathol. 1989;415:411–419.
   PubMedGoogle Scholar
• Nyström SN, Westermark GT. AA-amyloid is cleared by endogenous immunological mechanisms. Amyloid. 2012;19:138–145.
   PubMed Web of Science ®Google Scholar
• Chronopoulos S, Laird DW, Ali-Khan Z. Immunolocalization of serum amyloid A and AA amyloid in lysosomes in murine monocytoid cells: confocal and immunogold electron microscopic studies. J Pathol. 1994;173:361–369.
   PubMed Web of Science ®Google Scholar
• Lundmark K, Vahdat Shariatpanahi A, Westermark GT. Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis. PLoS One. 2013;8:e79104.
   PubMed Web of Science ®Google Scholar
• Kennel SJ, Macy S, Wooliver C, et al. Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice. Amyloid. 2014;21:45–53.
   PubMed Web of Science ®Google Scholar
• Claus S, Meinhardt K, Aumüller T, et al. Cellular mechanism of fibril formation from serum amyloid A1 protein. EMBO Rep. 2017;18:1352–1366.
   PubMed Web of Science ®Google Scholar
• Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol. 1981;11:805–815.
   PubMed Web of Science ®Google Scholar
• Borges da Silva H, Fonseca R, Pereira RM, et al. Splenic macrophage subsets and their function during blood-borne infections. Front Immunol. 2015;6:480.
   PubMed Web of Science ®Google Scholar
• Lundmark K, Westermark GT, Nyström S, et al. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA. 2002;99:6979–6984.
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Boudreau L. Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab Invest. 1983;48:53–59.
   PubMed Web of Science ®Google Scholar
• Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer’s disease beta-amyloid production. Biochim Biophys Acta. 2010;1801:860–867.
   PubMed Web of Science ®Google Scholar
• Aisenbrey C, Borowik T, Byström R, et al. How is protein aggregation in amyloidogenic diseases modulated by biological membranes? Eur Biophys J. 2008;37:247–255.
   PubMed Web of Science ®Google Scholar
• Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology. 2006;66:S74–S78.
   PubMed Web of Science ®Google Scholar
• Canale C, Oropesa-Nuñez R, Diaspro A, et al. Amyloid and membrane complexity: the toxic interplay revealed by AFM. Semin Cell Dev Biol. 2018;73:82–94.
   PubMed Web of Science ®Google Scholar
• Ganowiak K, Hultman P, Engström U, et al. Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun. 1994;199:306–312.
   PubMed Web of Science ®Google Scholar
• Puchtler H, Sweat F. Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem. 1965;13:693–694.
   PubMed Web of Science ®Google Scholar
• Sponarova J, Nuvolone M, Whicher C, et al. Efficient amyloid A clearance in the absence of immunoglobulins and complement factors. Am J Pathol. 2013;182:1297–1307.
   PubMed Web of Science ®Google Scholar
• Kumar S, Mohanty SK, Udgaonkar JB. Mechanism of formation of amyloid protofibrils of barstar from soluble oligomers: evidence for multiple steps and lateral association coupled to conformational conversion. J Mol Biol. 2007;367:1186–1204.
   PubMed Web of Science ®Google Scholar
• Knight JD, Miranker AD. Phospholipid catalysis of diabetic amyloid assembly. J Mol Biol. 2004;341:1175–1187.
   PubMed Web of Science ®Google Scholar
• Terakawa MS, Yagi H, Adachi M, et al. Small liposomes accelerate the fibrillation of amyloid β (1-40). J Biol Chem. 2015;290:815–826.
   PubMed Web of Science ®Google Scholar
• Wijesekara N, Kaur A, Westwell-Roper C, et al. ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice. Diabetologia. 2016;59:1242–1246.
   PubMed Web of Science ®Google Scholar
• Fantini J, Carlus D, Yahi N. The fusogenic tilted peptide (67–78) of α-synuclein is a cholesterol binding domain. Biochim Biophys Acta – Biomembr. 2011;1808:2343–2351.
   PubMed Web of Science ®Google Scholar
• Cabana VG, Lukens JR, Rice KS, et al. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res. 1996;37:2662–2674.
   PubMed Web of Science ®Google Scholar
• Vaisar T, Tang C, Babenko I, et al. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res. 2015;56:1519–1530.
   PubMed Web of Science ®Google Scholar
• Appelqvist H, Sandin L, Björnström K, et al. Sensitivity to lysosome-dependent cell death is directly regulated by lysosomal cholesterol content. Vekrellis K, editor. PLoS One. 2012;7:e50262.
   PubMed Web of Science ®Google Scholar
• Xue W-F, Homans SW, Radford SE. Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc Natl Acad Sci U S A. 2008;105:8926–8931.
   PubMed Web of Science ®Google Scholar
• Nogueira E, Gomes AC, Preto A, et al. Design of liposomal formulations for cell targeting. Colloids Surf B Biointerfaces. 2015;136:514–526.
   PubMed Web of Science ®Google Scholar
• Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002;22:197–224.
   PubMed Web of Science ®Google Scholar
• Sharma S, Mishra L, Grover I, et al. Liposomes: vesicular system an overview. Int J Pharm Pharm Sci. 2010;2:11–17.
   Google Scholar
• Röcken C, Menard R, Bühling F, et al. Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis. 2005;64:808–815.
   PubMed Web of Science ®Google Scholar
• Röcken C, Stix B, Brömme D, et al. A putative role for cathepsin K in degradation of AA and AL amyloidosis. Am J Pathol. 2001;158:1029–1038.
   PubMed Web of Science ®Google Scholar
• Jayaraman S, Gantz DL, Haupt C, et al. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. Proc Natl Acad Sci USA. 2017;114:E6507–E6515.
   PubMed Web of Science ®Google Scholar
• Das M, Gursky O. Amyloid-forming properties of human apolipoproteins: sequence analyses and structural insights HHS public access. Adv Exp Med Biol. 2015;855:175–211.
   PubMed Web of Science ®Google Scholar